We need you! Join our contributor community and become a WikEM editor through our open and transparent promotion process.
Mometasone
From WikEM
Contents
Administration
- Type: Inhaled corticosteroid
- Dosage Forms: 100, 200 mcg/actuation MDI
- Routes of Administration: Inhalation
- Common Trade Names: Asmanex HFA
Adult Dosing
- Prior medium dose inhaled steroid
- 2 puffs (100 mcg/actuation) q 12h
- Max: 800 mcg/day
- Taper to lowest effective dose
- 2 puffs (100 mcg/actuation) q 12h
- Prior high dose inhaled steroid
- 2 puffs (200 mcg/actuation) q 12h
- Max: 800 mcg/day
- Taper to lowest effective dose
- 2 puffs (200 mcg/actuation) q 12h
- Prior oral steorid
- 2 puffs (200 mcg/actuation) q 12h
- Max: 800 mcg/day
- Taper to lowest effective dose. Taper oral steroids gradually after > 1wk
- 2 puffs (200 mcg/actuation) q 12h
Pediatric Dosing
- 12+ yo, Prior medium dose inhaled steroid
- 2 puffs (100 mcg/actuation) q 12h
- Max: 800 mcg/day
- Taper to lowest effective dose
- 2 puffs (100 mcg/actuation) q 12h
- 12+ yo, Prior high dose inhaled steroid
- 2 puffs (200 mcg/actuation) q 12h
- Max: 800 mcg/day
- Taper to lowest effective dose
- 2 puffs (200 mcg/actuation) q 12h
- 12+ yo, Prior oral steorid
- 2 puffs (200 mcg/actuation) q 12h
- Max: 800 mcg/day
- Taper to lowest effective dose. Taper oral steroids gradually after > 1wk
- 2 puffs (200 mcg/actuation) q 12h
Special Populations
- Pregnancy Rating: C; Possible risk of teratogenicity based on animal data at 0.3-8x MRHD.
- Lactation risk: L3; Safety unknown
Renal Dosing
- Adult: Not defined
- Pediatric: Not defined
Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
- Asthma, acute
- Bronchospasm, acute
- Avoid abrupt withdrawal
Adverse Reactions
Serious
- Hypersensitivity reaction
- Anaphylaxis
- Bronchospasm
- Hypercorticisim
- Adrenal suppression
- Growth suppression (peds pts)
- Eosinophilia
- Churg-Strauss syndrome
- Glaucoma
- Cataracts
- Osteoporosis
Common
- Nasopharyngitis
- Headache
- Influenza
- Sinusitis
- Bronchitis
Pharmacology
- Half-life: 5h
- Metabolism: Liver; CYP450: 3A4 substrate
- Excretion: Feces 74%, Urine 8%
Mechanism of Action
Exact mechanism of anti-inflammatory action unknown. Inhibits multiple inflammatory cytokines and produces multiple glucocorticoid and mineralcorticoid effects.
